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The bZIP factor (HBZ) is an HTLV-1 regulatory protein
encoded by anti-sense transcription of the HTLV-1 gen-
ome. HBZ mRNA expression correlates with clinical dis-
ability in HAM/TSP patients – and can be reversed by
interferon (IFN) therapy. Sporadic evidence suggests
that HBZ may have a negative role on interferon signal-
ling. Activation of IRF3-dependent IFN signalling –
either direct induction of IFNb, viral restriction factors
or interferon stimulated genes (ISGs) – is crucial for
TLR and RLR mediated antiviral response. Thus, we
sought to determine whether HBZ can impair IRF3-
mediated innate immune responses. Over-expression of
active forms of RIG-I, MAVS, TBK1, IKKε or IRF3
alone drive an antiviral response – however, in the pre-
sence of an HBZ expression vector, IFNb responses
were abrogated by 50-70%. In contrast, HBZ enhanced
IRF7-dependent responses. In confirmation, both PBMC
and human astrocytes transfected with HBZ and subse-
quently stimulated with IFN-triggering ligands (LPS,
PolyI:C, VSV, Sendai virus and HTLV-1 virions), exhib-
ited impaired IRF3-dependent signalling as compared
with controls. As IRF3 is known to bind other bZIP pro-
teins, further studies are underway to delineate the nat-
ure of IRF-HBZ interactions. Identifying such a
mechanism may explain an enhanced risk of neurologic
infection, as we show that chronically HTLV-1 infected
astrocytes gradually increase and maintain long-term
HBZ expression. Defining the immunomodulatory prop-
erties of HTLV-1 HBZ protein will provide a vital con-
tribution toward understanding clinical outcome and
risk of opportunistic infection associated with HTLV-1
infection.
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